Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adult Subjects With Friedreich Ataxia

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adult Subjects With Friedreich Ataxia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs TAK 831 (Primary)
  • Indications Friedreich's ataxia
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 28 Sep 2018 Planned End Date changed from 27 Feb 2019 to 4 Jan 2019.
    • 28 Sep 2018 Planned primary completion date changed from 27 Feb 2019 to 4 Jan 2019.
    • 28 Sep 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top